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1Harvard Medical School and Harvard Pilgrim Health Care,
Boston, MA, USA; 2Kaiser Permanente, Oakland, CA, USA;
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OBJECTIVES: To measure preferences and willingness-
to-pay amounts for the change in health-related quality-
of-life associated with health states prevented by
pneumococcal conjugate vaccine.
METHODS: Preference and willingness-to-pay data were
collected for six health states preventable by pneumococ-
cal conjugate vaccine (simple otitis media, complex otitis
media, moderate pneumonia, severe pneumonia, menin-
gitis, bacteremia) and one vaccine-related adverse event
(fever and fussiness following vaccine). Two types of
respondents were interviewed: (1) parents of children
who had experienced one or more of the outcomes
described in the survey (n = 101), and (2) a US commu-
nity sample (n = 109). A phone-mail-phone survey
approach was employed so that respondents could refer
to health state descriptions and visual aids during the
interview. Preferences were measured using time-tradeoff
questions and willingness-to-pay was measured using
dichotomous-choice double-bounded questions with four
bid vectors.
RESULTS: Mean time-tradeoff and willingness-to-pay
amounts were consistently higher for the community
sample than the parent sample. Median time-tradeoff
amounts were also higher for community respondents for
most health states. The median amount of time traded off
for community respondents ranged from 6 days (otitis
media) to 1.5 years (bacteremia). The median responses
for parents ranged from 0 days (otitis media) to 1.1 years
(meningitis). Median willingness-to-pay amounts, how-
ever, were similar for the two samples. For example, both
parents and community respondents were willing-to-pay
$100 (median) to prevent one episode of otitis media and
$500 to reduce the risk of meningitis. Median willingness-
to-pay for a simpliﬁed description of the 4-dose series of
pneumococcal conjugate vaccine was $250 for parents
and $300 for community respondents.
CONCLUSIONS: Compared with parents, community
members tended to place higher values on preventing
pneumococcal-associated outcomes. The effect of differ-
ences in preferences by respondent type should be con-
sidered when incorporating quality-of-life adjustments
into economic analyses of pneumococcal conjugate
vaccine.
PIN16
AN ECONOMIC ASSESSMENT OF THE IMPACT
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OBJECTIVE: Urinary tract infections (UTIs) are among
the most common ailments encountered in primary 
care practice. Up to 50% of all women report having 
had a UTI during their lifetime. Several national treat-
ment guidelines recommend a ﬂuoroquinolone ﬁrst-line
for UTI in areas where Escherichia coli resistance to
trimethoprim-sulfamethoxazole (TMP/SMX) is >10–
20%. The current study developed a model to assess 
the economic impact of using ciproﬂoxacin, a ﬂuoro-
quinolone, ﬁrst-line in an area with high levels of E. coli
TMP/SMX resistance.
METHODS: The economic model utilized a treatment
algorithm from an IPA in southern California where the
reported TMP/SMX resistance rate was 38%. The IPA’s
standard treatment algorithm for uncomplicated UTIs,
which was incorporated into the model, included an
initial ofﬁce visit, dipstick urine, culture and sensitivity,
and prescription. If failure occurred, a second ofﬁce visit
and prescription were incorporated into the model. The
model’s clinical parameters included the local E. coli
resistance rates to TMP/SMX (38%) and to ciproﬂoxacin
(4%) and estimates of failure to the prescribed anti-
microbial (42%). Medicare reimbursement rates for ofﬁce
visits and laboratory costs, and drug costs of $1.62 for
TMP/SMX (800/160mg bid ¥ 3 days) and $10.43 for
ciproﬂoxacin (250mg bid ¥ 3 days), based on maximum
allowable cost, were used.
RESULTS: The total average treatment cost at the IPA
was $91.52 for a TMP/SMX-treated patient vs. $84.06
for a ciproﬂoxacin-treated patient. Resistance rates and
failure were the most signiﬁcant factors in driving 
treatment costs.
CONCLUSIONS: While cost of drug therapy is a factor
in antimicrobial selection, local resistance rates, failure
rates and the impact of total treatment cost should be
considered when developing treatment algorithms for
UTI. Extended recovery time and lost productivity are
implications of failure that may impact patient satisfac-
tion with the health plan and should be assessed in future
studies.
